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A B S T R A C T
Tuberculosis (TB) is a devastating threat to human health whose treatment without the emergence of drug
resistantMycobacterium tuberculosis (M. tuberculosis) is the million-dollar question at present. The pathogenesis of
M. tuberculosis has been extensively studied which represents unique defence strategies by infecting macro-
phages. Several anti-tubercular drugs with varied mode of action and administration from diversiﬁed sources
have been used for the treatment of TB that later contributed to the emergence of multidrug-resistant tu-
berculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). However, few of potent anti-tuber-
cular drugs are scheduled for clinical trials status in 2017–2018. Peptides of varied origins such as human
immune cells and non-immune cells, bacteria, fungi, and venoms have been widely investigated as anti-tuber-
cular agents for the replacement of existing anti-tubercular drugs in future. In the present review, we spotlighted
not only on the mechanisms of action and mode of administration of currently available anti-tubercular drugs
but also the recent comprehensive report of World Health Organization (WHO) on TB epidemic, diagnosis,
prevention, and treatment. The major excerpt of the study also inspects the direct contribution of diﬀerent
computational tools during drug designing strategies against M. tuberculosis in order to grasp the interplay be-
tween anti-tubercular peptides and targeted bacterial protein. The potentiality of some of these anti-tubercular
peptides as therapeutic agents unlocks a new portal for achieving the goal of end TB strategy.
1. Introduction
Tuberculosis (TB) is one of the oldest and deadliest airborne
asymptomatic tropical diseases in the world, caused by M. tuberculosis
(Mtb), infecting one third of the global populace. The disease remains a
devastating health issue in developing countries. TB can infect any parts
of the body but generally aﬀects the lungs. Development of TB outside
the lungs is termed as extra-pulmonary TB and occurs mainly in young
adults and immune suppressed persons. The “latent tuberculosis” is a
special type of TB when the infections are devoid of any symptoms and
progress to active disease if left untreated. In fact, in latent TB, Mtb
remains inside the body in inactive state and becomes active later on.
This type of TB is not contagious and persons aﬀected with latent TB do
not spread the disease and diagnosed by tuberculin skin test (TST) or
blood tests. The active TB can be transmitted to other person and di-
agnosis of active TB is solely relied on chest X-rays, microscopic ob-
servation, and culturing the body ﬂuids. The chronic cough, chillness,
blood-containing sputum, fever, night sweats, chest pain, fatigue, nails
clubbing, and weight loss are the classic symptoms of active TB.
“Osseous tuberculosis” is another type of tuberculosis where the in-
fection spreads to the bones. The bursting of a tubercular abscess
through skin causes tuberculous ulcer.
At present, the emergence of multidrug-resistant tuberculosis (MDR-
TB) and extensively drug-resistant tuberculosis (XDR-TB) has attracted
attention to attain eﬀective prevention, durable cure, and treatment of
the distending problems of TB. The major obstacle in the treatment of
TB is the unique mode of pathogenicity of Mtb. In fact, Mtb infects
human pulmonary macrophage and escapes from the phagocytosis
process. Mtb utilizes macrophages for its own replication process and
survives under the immoderate radical environment. In a nutshell, Mtb
arrests the maturation mechanism of phagosomes and prevents the
phagosomal acidiﬁcation. Further, it inhibits not only the synthesis of
lysosomes and phagosomes complex but also impairs the apoptosis of
macrophage as well as represses the antimicrobial actions, thereby
causing bacterial escape from the phagosomes. It is totally clear that
Mtb has potentiality to survive in the unfavourable conditions created
by host macrophage during the infection.
In addition to this, the association of TB with HIV infection is
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another considerable issue that caused 0.32 million mortality world-
wide [1]. These epidemiological problems shed light on the relevance
of the immune system to control TB and create a public health problem
among large population of human.
From the last century, BCG vaccine has shown some protective ef-
ﬁcacy in combating serious TB [2]. But the lack of protecting pul-
monary infections is the poor aftermath of this therapy and has been
called into the million-dollar question. In this regard, several anti-tu-
bercular drugs of distinct origins have been developed and used from
last few decades.
2. Anti-tubercular drugs: An overview
The treatment of TB consists of a multi-drug regimen with a long
duration of 6–8 months. The preferred ﬁrst-line anti-tubercular drugs
are isoniazid, rifampicin, pyrazinamide, and ethambutol. Second-line
drugs viz. streptomycin, kanamycin, ﬂuoroquinolones, ethionamide,
and p-aminosalicylic acid are used when the bacterial strain becomes
resistant to one or more of ﬁrst-line drugs. In general, second-line drugs
are less eﬀective and more toxic compared to the ﬁrst-line drugs.
Surprisingly, TB therapy is quite diﬀerent from the treatment of other
diseases due to the unique properties of MTb. Firstly, the treatment
involves a combination of several antibiotics to prevent the selection of
a resistant strain. Secondly, the antibiotics must be provided for a
minimum period of 6 months in order to eradicate the pathogen so that
there is no possibility of relapse after the completed course of treat-
ment. Finally, but most importantly, patients should be regularly
monitored throughout the treatment courses in order to observe any
drug-associated induced major/minor toxicities.
The pathogenesis of Mtb is inhibited by available anti-tubercular
drugs through various modes of action as shown in Fig. 1. In fact, TB is
curable, provided that the drug regime is followed diligently and thus,
avoiding the emergence of MDR-TB. Currently, there are several drugs
available for the treatment of TB. Table 1 shows not only the list of
drugs that are commonly used to cure TB but also their mode of action.
3. New anti-tubercular drugs: bedaquiline and delamanid in brief
From the last ﬁve decades, only two new anti-tubercular drugs were
approved and released. Bedaquiline is a ﬁrst-in-class diarylquinoline
compound that showed therapeutic potency against drug-sensitive and
drug resistant Mtb with a novel mode of action including the inhibition
of bacterial ATP synthase (by binding to subunit c of the enzyme), the
enzyme used by bacteria to generate energy. Hards et al. [25] clearly
showed the uncoupling process induced by bedaquiline. In a typical
Mtb cell, the majority of ATP synthesis is respiratory, driven by the
proton-motive force (PMF). The binding of bedaquiline to the c-ring
most likely perturbs the a-c subunit interface, thereby causing an un-
controlled proton leak uncoupled from ATP synthesis and resulting in a
futile proton cycle (Fig. 2). This drug is also known by the trade name of
‘Sirturo’. Bedaquiline is used in combination with other TB drugs to
treat pulmonary TB in adults with MDR-TB. It should only be used when
an eﬀective TB treatment cannot otherwise be provided and other drugs
are showing severe toxicity to patients. The use of bedaquiline is
avoided for the treatment of extra-pulmonary TB, drug sensitive TB,
latent TB infections, and infection caused by mycobacteria other than
Mtb. The recommended dose is 400 mg a day for two weeks and then
200 mg taken three times a week (with at least 48 h between doses) for
the next 22 weeks. In February 2016, it was announced that bedaqui-
line is to be made available in India and the drug will be available as
part of second line treatment for patients suﬀering from MDR-TB and
XDR-TB. The drug recently is under clinical trials phases in certain
hospitals of the country. This drug was approved based on the phase IIb
clinical trial results. However, phase III trials are still ongoing and its
ﬁnal approval is pending. There are issues with the safety concerns of
bedaquiline, related to QTc prolongation caused by the drug and the
Fig. 1. Diversiﬁed mode of action of existing anti-tubercular drugs. Thioamides, Nitroimidazoles, Ethambutol, Cycloserine, and Pyrazinamide are known to degrade the bacterial cell
wall. Aminoglycosides, Cyclic peptides, Fluoroquinolones, and PAS are known to eﬀect DNA coiling, transcription, and translation mechanism. ATP synthesis is inhibited by
Diarylquinoline.
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observed and yet unexplained higher mortality rate detected in the
group treated with bedaquiline compared to placebo. However, smaller
counts of patients showed lower mortality rate. A new phase III trial has
begun in order to investigate the safety and eﬃcacy of bedaquiline in
combination with short MDR-TB regimens of 9 and 6 months duration,
respectively.
Delamanid is another approved anti-tubercular drug, and the ﬁrst
drug of the nitroimidazole class to enter clinical practice. It is also
known by its trade name of ‘Deltyba’. It is currently being developed by
the Otsuka pharmaceutical company as a treatment for MDR-TB. The
drug is known to inhibit the synthesis of cell wall components of Mtb,
particularly methoxy mycolic acid and ketomycolic acid. Delamanid is
a pro-drug which gets activated by the enzyme deazaﬂavin dependent
nitroreductase. A reactive intermediate metabolite, formed between
delamanid and desnitro-imidazooxazole derivative, is considered to
play a pivotal role in the blockage of mycolic acid production (Fig. 3).
Similar to bedaquiline, a phase III trial on delamanid is ongoing. The
trial includes the use of this drug in combination with moxiﬂoxacin and
HIV-positive patients on antiretroviral therapy (ART). In addition to
this, other ongoing trials include assessing the use of delamanid for the
treatment of pediatric MDR-TB. Preclinical and clinical phase results
showed higher potency, lower risk for drug-drug interactions, and
Table 1
Commonly used anti-tubercular drugs, mechanism of action, and their mode of administration.
Anti-tubercular drug Mode of action Mode of administration References
Bedaquiline Causes electroneutral uncoupling of respiration-driven ATP synthesis and blocks ATP synthase in
Mtb.
Binding and perturbing the a-c subunit interface of the Fo, corresponding to futile proton cycle
and show anti-tubercular activity.
Oral [3]
Capreomycin Protein synthesis inhibition by interrupting the interaction between ribosomal proteins L12 and
L10
Intramuscular [4]
Cycloserine Interferes with early step bacterial cell wall formation inside the cytoplasm by competitive
inhibition of two enzymes, L-alanine racemase and D-alanylalanine synthetase.
Oral [5]
Ethambutol Disrupts arabinogalactan synthesis by blocking the arabinosyl transferase that leads to the
increased permeability of the cell wall.
Oral [6]
Isoniazid Blocking the natural enoyl-AcpM substrate and thus, inhibiting the fatty acid biosynthesis.
Finally it inhibits the mycolic acid synthesis.
Oral [7]
Kanamycin Inhibition of protein synthesis by irreversible binding to the cytosolic as well as membrane-
associated bacterial ribosome.
Intravenous [8]
Pyrazinamide Mode of action not clear but thought to disrupt the membrane transport. Oral [9]
Rifampin, Rifabutin, Rifalazil and
Rifapentine
Protein synthesis inhibition as well as induction of programmed cell death. Oral [10]
Nitroimidazoles Responsible for cell wall and DNA damage that causes DNA fragmentation, thereby inhibiting
DNA synthesis.
Oral [11]
AZD5847 Impairment of the mycobacterial 50S ribosomal subunit. Oral [12]
Fluoroquinolones Blockage of DNA replication. Intravenous [13]
Isoxyl Inhibition of mycolic acids and fatty acids biosynthesis. Pulmonary [14]
Ethionamide and Prothionamide Inhibit the synthesis of mycoloic acids. Oral [15]
Erythromycin and Roxithromycin Inhibition of protein synthesis. Oral [16]
p-aminosalicylic acid Inhibition of thymine nucleotides biosynthetic pathways. Oral [17]
Riminophenazines Inhibition of electron transport chain. Oral and parenteral [18]
Thiacetazone Disruptive characteristics of the permeability of cell envelope and host immunomodulation. Oral [19]
Delamanid Inhibition of mycolic acid synthesis. Oral [20]
Sutezolid Prevents the initiation of protein synthesis in bacteria by binding to 23S RNA. Oral [21]
Streptomycin Binds with 30S subunit of the ribosome and interferes with protein synthesis. Intramuscular [22]
Amikacin Binds with the small subunit 30S of the ribosome. Intramuscular [23]
Ciproﬂoxacin Targets the DNA gyrase. Intravenous [24]
Fig. 2. Mode of action of Bedaquiline on Mtb. Bedaquiline induces the uncoupling process by binding to the c-ring, thereby causing an uncontrolled proton leak uncoupled from ATP
synthesis (adapted from [25]).
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better tolerability of delamanid.
It is noteworthy that both bedaquiline and delamanid should only
be prescribed as part of a WHO-recommended regimen for patients with
MDR-TB in order to avoid the emergence of emergence of drug re-
sistance Mtb. It is possible that both the drugs would be given to the
same patient in the case of diﬃcult-to-treat patients. One of the major
challenges will be to ensure the availability of these drugs to all those in
need while keeping in mind the WHO policies.
Apart from above mentioned anti-tubercular drugs, there are also
few potent anti-tubercular agents in clinical trials status for the possible
development of new therapeutic drugs against TB. These anti-tuber-
cular agents are also known to inhibit the growth of Mtb through var-
ious mechanism of action as shown in Fig. 4. Most of them are in
preclinical development (40%), followed by Phase II (35%) and Phase
III (25%) phases. Of the new anti-tubercular agents under clinical trials,
only 5 are in Phase III and 7 are in Phase II trials. Additionally, 8 anti-
tubercular agents are under preclinical development phage, including 3
antimycobacterial agents in Good Laboratory Practice toxicity evalua-
tion. At present, there are no anti-tubercular drugs registered in Phase I.
Drugs under preclinical development may enter into Phase I in future.
Khusro and Aarti [26] reviewed the pivotal role of TB-PACTS (TB-
Platform for Aggregation of Clinical TB Studies) in making clinical trials
data of TB easily available. Authors further mentioned that TB-PACTS is
an invaluable data sharing approach in order to combat TB. In fact, it is
designed to catalyze and step up TB research by curating and stan-
dardizing Phase III TB clinical trials data and making those data easily
available to the scientiﬁc community.
4. A glance at current WHO report of TB
According to the latest report of WHO [27], there are increased total
counts for new TB cases globally than in last few years. In spite of the
recent advances and the fact for curing TB, the disease remains one of
the world's deadliest threats. The medications for the treatment of TB
can also lead to other serious health issues, such as kidney failure, liver,
or heart disorder, loss of vision or hearing, psychosis, and most im-
portantly HIV infection. Worldwide, 12% of the new TB cases are found
to be HIV-positive. In fact, HIV infection impels the risk of TB infection
on exposure, progression from latent infection to active, and ﬁnally a
risk of mortality if not treated both TB and HIV in time. Correspond-
ingly, TB is the most common opportunistic infectious disease and
cause of mortality among HIV infected persons.
The desideratum aim of WHO report 2017 is to provide a compre-
hensive and detail assessment of the TB epidemic and progress in di-
agnosis, prevention, and treatment globally. The report also targets a
90% reduction in the TB incidence rate (Fig. 5a) and 95% reduction in
TB deaths (Fig. 5b) in 2035, compared with levels in 2015 (per 100000
populations) in order to achieve End TB strategy. The 2030 targets are
an 80% reduction in the TB incidence rate and a 90% reduction in TB
deaths, compared with levels in 2015. The TB report 2017 establishes
an essential landmark worldwide in TB monitoring by WHO. There are
few important highlights of WHO 2017 reports as listed below.
• In 2016, there were an estimated 1.3 million TB deaths among HIV-
negative people (down from 1.7 million in 2000) and an additional
374000 deaths among HIV-positive people.
• An estimated 10.4 million people were infected with TB in 2016:
90% were adults, 65% were male, 10% were people living with HIV
(74% in Africa), and 56% were in ﬁve countries: India, Indonesia,
China, the Philippines, and Pakistan.
• In 2016, there were 600000 new cases with resistance to rifampicin,
the most eﬀective ﬁrst-line drug, of which 490000 had MDR-TB.
Almost half (47%) of these cases were in India, China, and the
Russian Federation.
• In 2016, 6.3 million new cases of TB were reported (up from 6.1
million in 2015), equivalent to 61% of the estimated incidence of
10.4 million; the latest treatment outcome data show a global
treatment success rate of 83%.
• There were 476774 reported cases of HIV-positive TB (46% of the
estimated incidence), of whom 85% were on ART.
• A total of 129689 people were started on treatment for drug-re-
sistant TB, a small increase from 125629 in 2015 but only 22% of
the estimated incidence; treatment success remains low, at 54%
globally.
• Ten countries accounted for 76% of the total gap between TB in-
cidence and reported cases; the top three were India (25%),
Indonesia (16%), and Nigeria (8%).
• Most of the estimated number of incident cases in 2016 occurred in
the WHO South-East Asia Region (45%), the WHO African Region
(25%), and the WHO Western Paciﬁc Region (17%); smaller pro-
portions of cases occurred in the WHO Eastern Mediterranean
Region (7%), the WHO European Region (3%), and the WHO Region
of the Americas (3%).
• The annual number of incident TB cases relative to population size
varied widely among countries in 2016, from under 10 per 100000
populations in most high-income countries to 150–300 in most of
the 30 high TB burden countries, and above 500 in a few countries
including the Democratic People's Republic of Korea, Lesotho,
Mozambique, the Philippines, and South Africa.
• Globally in 2016, 57% of notiﬁed TB patients had a documented
HIV test result, up from 55% in 2015.
• The treatment success rate for HIV-associated TB (2015 cohort) was
78% and for XDR-TB (2014 cohort) it was 30%.
• At least 35 countries have introduced shorter regimens for treatment
of MDR-TB. As part of eﬀorts to improve outcomes for MDR/XDR-
TB, 89 countries and territories had started using bedaquiline and
54 had used delamanid by June 2017.
Fig. 3. Mode of action of Delamanid against Mtb. Delamanid inhibits the synthesis of cell
wall components of Mtb, particularly methoxy mycolic acid and ketomycolic acid.
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• Funding for TB care and prevention reached US$ 6.9 billion in 2017
in 118 low and middle-income countries. This was an increase from
US$ 6.3 billion in 2016 and more than doubles the US$ 3.3 billion
that was available in 2006.
• India stood out as a country in which the budget envelope for TB
was substantially increased in 2017.
• Of the 10.4 million incident cases of TB in 2016, an estimated 1.9
million were attributable to undernourishment, 1.0 million to HIV
infection, 0.8 million to smoking, and 0.8 million to diabetes.
• There are 17 drugs in Phase I, II or III trials, including eight new
compounds, two drugs that have received accelerated or conditional
regulatory approval based on Phase IIb results, and seven re-
purposed drugs. Various new combination regimens are in Phase II
or Phase III trials.
• There are 12 vaccine candidates in clinical trials: three in Phase I,
and nine in Phase II or Phase III.
• TB incidence is falling at about 2% per year and 16% of TB cases die
from the disease; by 2020, these ﬁgures need to improve to 4–5%
per year and 10%, respectively, to reach the ﬁrst (2020) milestones
of the End TB Strategy.
Fig. 4. Mode of action of anti-tubercular agents under drug developmental pipeline. Nitroimidazoles, SQ-109, Meropenem, and Benzothiazinones inhibit the synthesis of bacterial cell
wall. Rifamycins, Oxazolidinones, and Macrolides are known to aﬀect DNA coiling, transcription, and translation processes. Imadazopyridine amide inhibits the ATP synthesis of bacteria.
Fig. 5. WHO reports the targets of (a) a 90% reduction in the TB incidence rate and (b) 95% reduction in TB deaths in 2035, compared with levels in 2015 (per 100000 populations).
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5. Anti-tubercular/antimicrobial peptides and molecular mode of
action
Anti-tubercular peptides are naturally synthesized endogenous oli-
gopeptides containing diﬀerent numbers of amino acids that shows
plausible antimycobacterium activity. In fact, anti-tubercular/anti-
microbial peptides belong to gene-encoded peptides that show direct
growth inhibitory activity against several Mycobacterium species,
especially Mtb and devote a key appearance in host defence me-
chanism. Development of MDR- and XDR-Mtb has heightened the im-
perative to understand the mode of operation of peptides in response to
bacterial targets. Generally, cationic antimicrobial peptides (AMPs)
interact with the anionic surface of bacterial membrane, thereby
causing the conglomeration of peptide molecules on the membrane. A
speciﬁc peptide–lipid complex is formed after the hydrophobic inter-
action between the AMPs and the bacterial membrane, thereby pro-
ducing the possible alteration in the structure of bacterial membrane
[28]. The modiﬁcation favours the translocation of peptides across the
cell membrane and targets the intracellular components such as en-
zymes, nucleic acids, and other organelles by diﬀusing into the cyto-
plasm.
The barrel-stave model, the toroidal model, and the carpet model
are commonly acknowledged for killing the bacteria (Fig. 6). In the
barrel-stave model, the peptides arrange themselves in order to bind to
the cell membranes, thereby causing the transformation of the peptide
into a bilayer. Therefore, the hydrophobic peptides are arranged in line
with the lipid centre, while the hydrophilic peptides create an access
pore in the internal section of the membrane. The carpet model involves
disruption of the membrane through peptide binding to the external
layer of the cell membrane, thereby creating a carpet. In the toroidal
model, the attached peptides begin to compel the lipid monolayer to
constantly bend through the pores. Thus, the core is lined by the in-
serted peptides as well as lipid head groups [29,30].
Previous report has demonstrated the antimycobacterial activity of
peptides by increasing the permeability of bacterial cell wall [31]. The
distinctive cell wall composition of Mtb contributes to its pathogenicity
nature and acts as an impediment to the ingress of anti-tubercular
peptides/drugs. In fact, the bacterial cell surface is hydrophobic due to
the high content of lipid and mycolic acids with long hydrocarbon
chains. This extremely unique characteristic of Mtb induces the ag-
gregation of the cells and consequently aﬀects the permeability of the
cell wall [32]. AMPs could also incite the cell membrane permeability
not only by creating pores but also disrupting the mechanisms of cell
wall synthesis. There are also few reports discussing the AMPs with
more than one mode of anti-tubercular action. Carroll et al. [33] de-
monstrated that lantibiotics such as nisin and lacticin 3147 bind to the
peptidoglycan precursor and thus, altering the biosynthesis of pepti-
doglycan as well as creating pores in the cell membrane. Uridyl-peptide
antibiotics might inhibit bacterial translocase MraY and exhibit anti-
mycobacterial property. The growth inhibitory characteristic of myco-
bacterium with similar mode of action was reported by Li et al. [34].
6. Physiochemical parameters for antimicrobial peptides
Amphipathicity nature of peptides is an imperative physiochemical
factors required for their growth inhibitory action against the bacteria.
In general, amphipathicity ensures the commencing interaction be-
tween peptides and bacterial membrane, and thereby helps the binding
Fig. 6. Understanding the mechanism of action of anti-tubercular/antimicrobial peptides against Mtb through barrel-stave model, the toroidal model, and the carpet model (adapted from
[30]).
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of peptides with membrane surface. Almost all peptides form amphi-
pathic structures upon interaction with target bacterial membranes.
The disulphide bonds existing in the structure of peptides stabilize and
induce the antimycobacterial activity [35].
Hydrophobicity is another important parameter inﬂuencing the
bioactivity of peptides. Peptide hydrophobicity is the percentage of
hydrophobic residues within a peptide and hydrophobicity administers
the intensity to which a peptide can partition into the lipid bilayer.
According to the report, the eﬃciency of antimycobacterial activity is
intensiﬁed due to the balance between the hydrophobicity of selective
peptide and its polar regions [36]. An increase in the hydrophobic
moment results in a signiﬁcant increment in the permeabilizing prop-
erties of peptides against bacterial membranes. Previous reports de-
monstrated that an increase in the hydrophobicity on the positively
charged side of a peptide below a threshold range can induce its ac-
tivity, while decreasing hydrophobicity might have negative impact on
the bioactivity of peptides [37], demonstrating an optimal hydro-
phobicity for selective peptide, beyond which its activity subsides [38].
Therefore, the hydrophobicity under optimum range will help to design
synthetic peptides dexterously.
The length of a peptide plays an exceptional role in designing a new
synthetic peptide. A minimum of 7–8 amino acids are required to form
amphipathic structures with hydrophobic and hydrophilic regions on
the reverse sides of a peptide. The size for a peptide to transverse the
lipid bilayer of the bacterium in the barrel-stave model should be no-
ticeably 22 and 8 amino acids for α-helical and β-sheet peptides re-
spectively. Generally, a peptide with shorter residues exhibit less toxi-
city that contributes in the development of ultramodern synthetic
peptides.
The net charge of selective peptides is one of the leading aspects for
the initial interaction with negatively charged bacterial membranes.
The bioactivity of peptides can be induced by altering the net charge of
the peptide without any side eﬀects on the host. Similarly, solubility of
peptides is a major framework because peptides should ingress through
lipid membranes, and thus they need to be soluble in aqueous en-
vironments.
Apart from the above mentioned physiochemical parameters, it is
obligatory to ﬁnd out if a candidate peptide is toxic for host cells. The
cytotoxicity activities of peptides are not exercised to its anti-tubercular
activity due to the diﬀerence in the structural property of candidate
peptide [39]. The study has demonstrated that enniatins from fungal
genera such as Alternaria, Fusarium, Halosarpheia, and Verticillium
evoked toxicity using in vitro assays [40]. Sharma et al. [41] reported a
reduced toxicity of HNP-1 towards the macrophage cell line at a con-
centration inhibitory to mycobacterium, thereby suggesting the low
toxicity because of the presence of FBS in the culture media. It is highly
recommended to ﬁnd new anti-tubercular peptides with reduced or null
toxicity to human cells.
7. Anti-tubercular peptides and Mtb: A computational approach
Novel drug targets identiﬁcation depends upon the identiﬁcation of
essential genes present in the bacterium. The genome sequence of pa-
thogenic bacteria provides a tremendous amount of information that
can be utilized in drug target identiﬁcation against pathogen with re-
spect to the host. The application of computational tools such as mo-
lecular dynamics, docking, and modelling are often being used in order
to understand the protein complexes involved in mycobacterium in-
fections. Computational approaches or in silico studies provide oppor-
tunities to ﬁnd the potential drug targets from proteome analysis. At
present, the computational approach has replaced the experimental
tools in order to understand the physicochemical and structural prop-
erties of proteins. Proteins are the building block and are located in the
sub-cellular compartment such as outer membrane, the inner mem-
brane, periplasm, cytoplasm, and extracellular of prokaryotes. The
identiﬁcation of various sub-cellular proteins contributes in designing
and developing novel anti-tubercular drugs. The structural modelling of
these proteins can help to determine which of these proteins can
function as most eﬀective surface epitope for the drug that can lead to
the discovery of novel therapeutic anti-tubercular drug. On the other
hand amino acid sequences determine and characterize molecule's
functional, physical, and chemical properties.
Host-pathogen protein interactions (HPIs) play a versatile role in the
pathogen's ability to invade the host and escaping from host's immune
defences. Experimentally, the yeast two-hybrid (Y2H) system, lumi-
nescence-based mammalian interactome mapping, and co-im-
munoprecipitation (coIP) coupled with mass spectrometry (MS) are
main approaches to detect the interacting proteins [42]. But these
techniques are not only time-consuming but also an expensive ap-
proach. Hence, computational methods have been considered to iden-
tify the protein-protein interaction (PPI) that is based on protein se-
quences, structural, and genomic features. Interologs (homologous PPI)
is based on the assumption that homologous proteins preserve their
potential to interact [43] and detect host-pathogen protein interactions
[44].
At present, the complete genome of Mtb and the host Homo sapiens
has been sequenced that insights the prediction of host-bacteria protein
interaction. It helps to compile a list of potential gene products and
identify the functions present in the human and absent in Mtb. It has
solved the major problem of searching for potential drug targets. The
anti-tubercular peptides are also known for inhibiting the bacterial
enzymes and therefore, these enzymes can be drug targets. There are
several pathways that can be targeted for rational drug design. Few
targets such as thiamine metabolism, peptidoglycan biosynthesis,
polyketide sugar unit biosynthesis, D-Alanine metabolism, fatty acid
biosynthesis path1, fatty acid metabolism, phospholipid degradation,
glycerolipid metabolism, ubiquinone and menaquinone biosynthesis,
lysine biosynthesis, pyrimidine metabolism, purine metabolism, ni-
trogen metabolism, nucleotide sugar metabolism, inositol phosphate
metabolism, and glycerolipid metabolism had been recommended for
designing a drug against Mtb [45].
Glutamine synthetase is an important enzyme that produces the
condensation reaction along with glutamate [46]. It is considered as a
central part of the bacterial nitrogen mechanism and catalyzes the
glutamate. It leads to the formation of glutamine and hydrolysis of ATP.
This enzyme is available in the brain and kidney. In the brain, it binds
with glutamate regulation that leads to the detoxiﬁcation of ammonia,
and ﬁnally terminates the neurotransmitter signals. Tryptophan, histi-
dine, alanine, glycine etc. can inhibit glutamine synthetase. This en-
zyme is an essential target for maximum number of anti-tubercular
drugs.
RNA polymerase is yet another crucial enzyme that catalyzes the
synthesis from a DNA template [47]. It is also called as DNA-dependent
RNA polymerase. The enzyme is very essential for the growth and
survival of the mycobacterium. This intracellularly targeted enzyme is
known for the transcription and termination of DNA sequence. Perumal
et al. [48] performed the molecular docking studies of short peptides
related to human histatin and apidaecin intolerant asthma against
glutamine synthetase and RNA polymerase respectively. Authors also
compared the anti-tubercular potential of peptides with reference to the
standard anti-TB drug such as rifampicin, isoniazid, amikacin, and ci-
proﬂoxacin. According to their reports, aspirin-intolerant asthma (AIA)-
II and AIA-I showed activity against the glutamine synthetase with
GLIDE score (G score) of −8.79 and −7.97 as compared to standard
amikacin and ciproﬂoxacin with G score of −7.71 and −3.45. On the
other hand, AIA-I, AIA-II, and HH-I showed potency against RNA
polymerase with G score of−10.12,−9.47, and−8.74 in comparison
to rifampicin and isoniazid with G score of −6.57 and −3.34. The
ﬁndings proved that the docked aspirin-intolerant asthma (AIA)-II and
AIA-I could be utilized for developing new chemical entity against Mtb.
The G score can be applied as a semi-quantitative descriptor and con-
ﬁrmed that above inhibitors are suitable as the binding pocket of the
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glutamine synthetase and RNA polymerase receptors. Based on their
outcomes, the authors recommended exploring the novel peptides as
anti-tubercular agents.
Menaquinone is a lipid-soluble naphthoquinone that is necessary for
various pivotal functions of bacteria and it serves as an electron
transporter in the respiratory chain for their survival strategy. The
chorismate of the shikimate pathway in bacteria induces the synthesis
of naphthoquinone. The menaquinone has been an attractive target for
the development of potential drug against Mtb due to its absence in
humans and animals.
O-succinylbenzoate synthase (OSBS) plays a pivotal role and it is
one of the major potential drug targets in shikimate pathway. In spite of
the availability of several anti-tubercular drugs, this enzyme has been
taken into account due to the emergence of MDR-TB and XDR-TB. Mtb-
O-succinylbenzoate synthase (Mtb-OSBS) converts 2-succinyl-6-hy-
droxy-2,4-cyclohexadiene-1-carboxylate (SHCHC) into 4-(2′-carbox-
yphenyl)-4-oxobutyrate (O-succinylbenzoate or OSBC or menC) via an
elimination of water. Pulaganti et al. [45] developed ﬁrst time the 3-D
structure of Mtb-OSBS followed by its structural annotations. The 3-D
model of Mtb-OSBS was built using structure coordinates of Thermo-
biﬁda fusca. Further, substrate-based analogue and auxiliary molecule
interaction energies with Mtb-OSBS were systematically evaluated
using molecular dynamic simulation and molecular docking strategies
in order to develop active drugs against Mtb-OSBS. The active site
amino acids had been identiﬁed by comparing the template sequence
with the Mtb-OSBS sequence. The authors identiﬁed that Lys108, Asn140,
Asp138, Lys110, Glu189, Ser236, Asp188, Arg27, Tyr52, and Ser237 are
highly conserved, and these may contribute as active
residues. Authors screened 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-
carboxylate (SHCHC) through AutoDock 4.0. and the SHCHC molecule
was further modiﬁed structurally and optimized through PRODRG
server. MD simulation showed the stable conformation annotations of
Mtb-OSBS and proved hypothetically to develop better anti-tubercular
drugs.
In the line of exploring computational tools to design and devel-
oping novel drugs against Mtb, Huo et al. [49] developed a systematic
ﬂow to predict the interaction between Mtb and H. sapiens based upon
sequence motifs. Protein sequences were used as an initial input to
identify the interaction between Mtb and H. sapiens by ‘interolog’
method and further ﬁltered by domain-domain interactions (DDIs)
prediction. As a result of this, 118 pairs of host-pathogen interactions
were identiﬁed, constituting 43 proteins from Mtb and 48 proteins from
H. sapiens. The computational tools such as VisANT, Reactome, Inter-
oPorc, IntAct, DIP, MPIDB, MINT, and HPRD were applied to predict
intra-species PPIs for the proteins from Mtb and H. sapiens [50–57].
A new specialized database named PATH (Protein interactions of
Mtb and Human) was constructed in order to store those predicted
interactions and proteins. A total of 118 credible HPIs were identiﬁed
and stored in the PATH. The database supports the search related to the
interspeciﬁc and intraspeciﬁc interactions between MTb and human,
MTb's gene locus, Uniprot ID, and might facilitate the understanding of
mechanism behind the TB infection. The PATH database may help to
develop new anti-tubercular drugs and may shed light on the interac-
tion between Mtb and its host. In fact, PATH was built on an Nginx with
Python and a MySQL Server as the back-end. Hyper Text Markup
Language (HTML), JQuery, and Cascading Style Sheets (CSS) were
applied at the front-end.
Generally, the selection of suitable antimicrobial peptides against
the target pathogens depends upon the several parameters. The
Isoelectric point (pI) determines the solubility and the mobility of
peptide or protein of interest. Computed pI values of proteins greater
than 7 indicate the basic nature of protein. The isoelectric point is
useful to develop a buﬀer system for the puriﬁcation by isoelectric fo-
cusing method and also to determine half life of protein [58]. The in-
stability index determination is another parameter for the selection of
suitable peptides. The protein with instability index value lower than
40 is predicted as stable, while greater than 40 is considered as un-
stable. The grand average hydropathy (GRAVY) value for a peptide is
calculated by dividing the sum of hydropathy values of all amino acids
to the number of residues in the sequence. The lower GRAVY range
indicates the hydrophilic nature of the peptides. SOSUI predicts the
transmembrane helices for soluble proteins. Self Optimized Prediction
Method with Alignment (SOPMA) predicts the secondary structures of
proteins. The secondary structure demonstrates the helical, strand or
coil nature of the given amino acids. The three homology modelling
programs, Swiss Model server, Modeller, and EsyPred3D web Server
help to model the 3-D structure of the peptides or proteins of interest
and contribute in the selection of the best model. The lower Emin value
predicts the suitability of peptides of interest for designing therapeutic
drugs.
In response to the above mentioned parameters for designing ther-
apeutic drugs from antimicrobial peptides, Bhagat et al. [58] performed
docking study with antimicrobial peptide, aurein 1.2 along with
available drugs such as pyrazinamide, ethambutol and isoniazid against
three proteins (NP_216679, NP_218309, NP_218312) of Mtb as poten-
tial targets. Among these proteins chosen, NP_218312 was found to be
the most stable structure with good stereo-chemical properties, thereby
making this protein of interest as an eﬀective target. Aurein1.2 was
found to be the most potent anti-tubercular peptide than other drugs
investigated and was recommended for designing an emphatic drug
against Mtb.
The cytosolic Fau protein (a microbicidal peptide precursor) is
composed of ubiquitin-like domain FUBI at N-terminus and ribosomal
protein rpS30 at C-terminus. Fau has been important in killing of in-
tracellular Mtb infection through autophagy-targeting p62 mechanism.
The p62 adaptor protein delivered rpS30 to autolysosome where it was
converted into antimicrobial peptides capable of killing Mtb in myco-
bacterial phagosome. Autophagy is a homeostatic process of eukaryotic
cells that exposes cytoplasmic components, proteins, organelles, and
various intracellular pathogens to lysosomes for their digestion. The
autophagy degrades intracellular microbial pathogens by two principal
methods. First, autophagosomes directly engulf free cytosol micro-
organisms that marked with poly-ubiquitin complexes through adaptor
protein such as p62 and NDP52 [59], and then delivered for its elim-
ination. Second, autophagy exposes Fau protein (a precursor of rpS30
peptides which was converted into microbicidal ribosomal protein by
proteolytic enzyme in autolysosome) to the phagosome of Mtb through
p62 autophagy adaptor proteins. The UBA domain of p62 proteins di-
rectly bind with Fau, as indicated by immunoﬂuorescence microscopy
and immunoprecipitation.
FUBI had ability to interact to the p62 UBA domain directly [60].
FUBI and p62 UBA domain are members of protein family UBL (ubi-
quitin-like) and UBD (ubiquitin-binding domain), respectively, and
binding interactions between UBL and UBD have been reported [61]. In
this regard, Chongruchiroj et al. [62] elucidated the interaction be-
tween FUBI and p62 UBA. Based upon the conserved hydrophobic re-
gions of FUBI and p62 UBA domain, a total of 334 docked poses were
predicted. A plausible structure of FUBI in complex with p62 UBA do-
main was obtained by several computational tools such as ZDOCK,
RDOCK, MD simulations, and MM-PBSA binding free energy calcula-
tion. Based on this, ﬁve possible binding modes were illustrated with
diﬀerent orientations of p62 UBA domain with respect to FUBI. How-
ever, only two binding mode structures were found to be stable after 15
ns of MD simulations. On the other hand, their MM-PBSA binding en-
ergies were analyzed to demonstrate the potent FUBI-p62 UBA complex
structure. Thus, the report enlightened the interaction between p62 and
Fau which is a very prominent step of autophagy-targeting p62 me-
chanism for the growth inhibition of Mtb.
The presence of mycolic acid in the outer membrane is an important
criterion for the existence and pathogenicity of Mtb. In fact, mycolic
acids are hydroxyl fatty acids containing long alkyl side chains that
allow the bacterium to condone and sustain inside the macrophages by
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protecting it against host's immune systems. The bacterium secretes
mycolyl transferases with molecular weight ranging from 30 kDa to
35 kDa, called as antigen-85 protein complexes (Ag85A, Ag85B, and
Ag85C). They are mainly responsible for the synthesis of mycobacterial
cell wall. Mycolyl transferase catalyzes the transfer of mycolic acid and
induces the synthesis of bacterial cell wall. In view of the pivotal role of
mycolyl transferase in the synthesis of bacterial cell wall, they are in-
ferred as an ideal target for the TB treatment. In general, these bioactive
proteins catalyze the transfer of mycolic acid from one trehalose 6-
monomycolate (TMM) to another, and forms trehalose 6,6-dimycolate
(DMM) as well as free trehalose.
Dermcidin is one of the antimicrobial peptides which is encoded by
the DCD gene in human being and often secreted by sweat gland cells to
provide a broad spectrum antibacterial activity against several patho-
gens. From this point of view, Banerjee and Gohil [63] demonstrated
the binding interaction between the dermcidin and mycolyl transferase
using AutoDock Vina, a computational docking strategy. They con-
cluded and postulated that dermcidin has the ability to interact with
FbpA (target for ligand binding) in order to inhibit the transfer of
mycolic acid to the peptidoglycan layer of the bacterial cell wall and
ultimately interfering with the synthesis of cell wall. According to the
report, the Global Model Quality Estimation (GMQE) score for the
modelled protein was found to be 0.98, which indicated the accuracy of
the model and the docked model was visualized using PyMol. In ad-
dition to this, the study also reported the lowest energy value (5.6 kcal/
mol) relative to previous reports, and therefore, the model was con-
sidered the best ﬁt.
Toxin-antitoxin (TA) systems contribute in multidrug tolerance and
bioﬁlm formation properties of bacteria. TA systems have been proved
to be targets to develop oﬀbeat anti-tubercular agents [64] because the
bactericidal agents disrupt the interaction of the TA complex that may
lead cells to death [65]. The VapBC family (47 of 88 putative TA sys-
tems) constitutes more than half of the TA systems in Mtb [66], and
vapBC loci are responsible for bacterial persistence and pathogenicity
factors [67]. In order to develop novel anti-tubercular agent, Lee et al.
[68] concentrated on VapBC Systems of Mtb. The ﬁnding reported that
Mtb VapC30 toxin maintained the growth through both the magnesium
and manganese ion-dependent ribonuclease activity and was inhibited
by the cognate VapB30 antitoxin. The study led to design VapB30 and
VapC30-associated new peptides which successfully disrupted the
toxin-antitoxin complex and thus activated the ribonuclease activity of
the VapC30 toxin. The study reported the designed peptides that mimic
the helical regions of the toxins in the heterodimer interface of the
VapBC30 complex, and disrupt the binding between VapBC30 com-
plexes. The approach may prove to be a potential candidate in TB
treatment. The VapBC5, VapBC3, and VapBC15 complexes are the
major types of Mtb VapBC family members [69] whose structural in-
formation and functional mechanisms are still elusive.
Keeping in view of the previous in silico studies, docking strategy
proved to be an eﬀective approach for the designing and developing
new anti-tubercular drugs from the peptides. This novel approach paves
a new way for worldwide researchers to investigate further the re-
searches in depth, based on the data obtained through computational
studies. The systematic computational analysis conducted in the pre-
vious reports may contribute in designing better drugs for the treatment
of TB. The computer-aided tools put forth a foundation for screening
several anti-tubercular peptides from diverse sources in order to de-
velop novel drugs for the TB therapy.
8. Concluding remarks and future perspectives
TB is a global endemic disease that has become obligatory to treat
due to the emergence of MDR- and XDR-Mtb. Currently available
frontline anti-tubercular drugs are failing to prevent spread of the dis-
ease and causing the development of resistant strains due to the unique
pathogenicity of Mtb. WHO reported that new drugs will be required to
achieve the targets set in the End TB strategy. Anti-tubercular peptides
from diverse sources might be a suitable and eﬀective alternatives of
existing antimycobacterium drugs due to their broad spectrum activity
against Mtb. Studying the systematic computational analysis between
peptide structure and its molecular mode of action will lead to design
and develop novel drugs with desired mycobactericidal activities that
may create a new era for the possible eradication of TB in future.
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